Dr. Reddy's OTC Guaifenesin and Pseudoephedrine HCl is used to help loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive; temporarily relieve nasal congestion due to common cold, hay fever, and upper respiratory allergies; temporarily restore freer breathing through the nose; promote nasal and/or sinus drainage; and temporarily relieve sinus congestion and pressure.
The Mucinex D brand and store brands had combined US sales of approximately USD71 m MAT for the most recent twelve months ending in May 2019 according to IRI.
Dr. Reddy's OTC Guaifenesin 1200 mg and Pseudoephedrine HCl 120 mg is available in 24-count packages. Dr. Reddy's OTC Guaifenesin 600 mg and Pseudoephedrine HCl 60 mg is available in 18- and 36-count packages.
Mucinex is a trademark of RB HEALTH LLC
Dr. Reddy's Laboratories is an integrated pharmaceutical company. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.
Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Its major markets include USA, India, Russia and CIS countries, and Europe.
Civica Rx, Hikma to Ship Heparin and Seven Other Essential Injectable Medicines
Novartis reveals results from two analyses of real-world experience with Kymriah
Samyang Biopharm USA partners with Talix Therapeutics NV to advance novel immuno-oncology therapy
AbbVie collaborates with Scripps Research
Oncternal Presents Clinical Data Update on Cirmtuzumab in Combination with Ibrutinib
First Patient Dosed with Third ImmTAC Bispecific
Biovica names new SVP Business Development
CStone Pharmaceuticals names new general manager for Greater China and head of Commercial
FerGene reveals positive results from Phase three nadofaragene firadenovec clinical trial
CARsgen Therapeutics wins IND clearance in China for AB011 humanized Claudin18.2 monoclonal antibody